• ABOUT ELITE
    • Overview
    • Our Facility
    • Management & Key Employees
    • Our Board
    • Careers
  • PRODUCTS
  • PIPELINE
    • Generic
    • Branded
  • TECHNOLOGY
    • Technology Overview
    • How It Works
    • One Bead System
    • Two Bead System
  • INVESTOR RELATIONS
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Shareholder Meeting
    • Governance Documents
    • Investor Contacts
    • Email Alerts
logo image
HOME | CAREERS | CONTACT | NEWS |
Share
Skip to content
  • About Elite
    • Overview
    • Management & Key Employees
    • Our Board
    • Careers
  • Products
  • Pipeline
    • Generic
    • Branded
  • Technology
    • Technology Overview
    • How It Works
    • One Bead System
    • Two Bead System
  • Investor Relations
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Shareholder Meeting
    • Governance Documents
    • Investor Contacts
    • Email Alerts
    • Investor Relations
    • Press Releases
    • Events &
      Presentations
    • SEC Filings
    • Shareholder
      Meeting
    • Governance
      Documents
    • Investor Contacts
    • Email Alerts

Press Releases
 
Select:
Feb 14, 2024
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
Feb 08, 2024
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
Dec 26, 2023
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant
Dec 12, 2023
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR® to Marketing Partner Prasco, LLC
Nov 14, 2023
Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information
Nov 10, 2023
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023
Sep 25, 2023
Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product
Sep 07, 2023
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer
Aug 28, 2023
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Aug 14, 2023
Elite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call Information
 1   2     3    4   5   6   7   8 
 <<   <   >   >> 
  • Site Map   |  Privacy  |  Terms Of Use
Copyright © Elite Pharmaceuticals Inc. | All Rights Reserved.
ART™: Abuse-Resistant Technology for a safer healthier you.
Back to top

Privacy
Resize Viewer - Reduce Resize Viewer - Expand Close window